Capstone Investment Advisors
NKTR icon

Capstone Investment Advisors’s Nektar Therapeutics NKTR Stock Holding History

Capstone Investment Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
+6,902
New +$505K ﹤0.01% 1256
2020
Q2 		– Sell
-121
Closed -$32K – 1352
2020
Q1 		$32K Sell
121
-2,534
-95% -$784K ﹤0.01% 1091
2019
Q4 		$860K Buy
2,655
+1,051
+66% +$305K ﹤0.01% 1035
2019
Q3 		$438K Buy
1,604
+760
+90% +$279K ﹤0.01% 1118
2019
Q2 		$451K Sell
844
-97
-10% -$48.6K ﹤0.01% 1130
2019
Q1 		$474K Buy
941
+550
+141% +$326K ﹤0.01% 1010
2018
Q4 		$193K Buy
391
+135
+53% +$81.5K ﹤0.01% 1033
2018
Q3 		$234K Buy
+256
New +$219K ﹤0.01% 973
2018
Q1 		– Sell
-440
Closed -$394K – 488
2017
Q4 		$394K Buy
+440
New +$260K 0.01% 312

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's NKTR Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 6,902 shares worth $482K. The stake represents ﹤0.01% of the portfolio and ranks #1256 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in NKTR as recently as Q1 2020.

Capstone Investment Advisors first reported a position in NKTR in Q4 2017 and has held it in 9 quarters since. The position peaked at $860K in Q4 2019. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Capstone Investment Advisors held 6,902 shares of Nektar Therapeutics worth $482K as of Q2 2026.
  • Nektar Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1256 holding.
  • Capstone Investment Advisors first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 9 quarters since.
  • Capstone Investment Advisors's Nektar Therapeutics position peaked at $860K in Q4 2019.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.